STRUCK Study design.
The primary efficacy outcome (improvement in the WHO scale of ≥2 points) occurred in 14 (100%) participants assigned to the colchicine group, 13 (81.3 %) participants in the ixekizumab and SOC groups, and 9 (64.3%) participants in the low-dose IL-2 group (
